• If you are wondering whether Haemonetics at around US$59.26 is a bargain or just fairly priced right now, this article walks through what the numbers say about its value.
• The stock has seen mixed returns, with a 1.1% decline over the last 7 days, a 4.3% gain over 30 days, and year to date and 1 year returns of 25.9% and 7.2% declines. These movements may be prompting new questions about risk and opportunity.
• Recent news coverage has focused on Haemonetics as part of broader discussions around medical equipment stocks. This can shift how investors view the sector compared with other areas of healthcare and helps explain why some investors are reassessing companies with similar profiles, even without company specific headlines driving the share price.
• Haemonetics currently has a valuation score of 5 out of 6. The sections that follow break down how different valuation methods line up on the stock, and they introduce a more complete way to think about value at the end of the article.

Approach 1: Haemonetics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today. It focuses on the cash the business is expected to generate for shareholders rather than short term market sentiment.

For Haemonetics, the 2 Stage Free Cash Flow to Equity model starts with last twelve month Free Cash Flow of about $304.0 million. Analysts provide specific forecasts for the next few years, including an estimate of $277 million in Free Cash Flow for 2028. Beyond those analyst inputs, Simply Wall St extrapolates cash flows out to 2035, with annual projections such as $179 million in 2026 and $298.9 million in 2035, each discounted back to a present value.

Putting these cash flow projections together gives an estimated intrinsic value of $90.43 per share. Compared with the recent share price of about $59.26, the DCF output implies the stock is around 34.5% below this intrinsic estimate. This suggests that, based on this model, Haemonetics may be trading at a discount to the calculated intrinsic value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Haemonetics is undervalued by 34.5%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Haemonetics Price vs Earnings

For profitable companies, the P/E ratio is a useful way to link what you pay for each share to the earnings that business is currently generating. A higher or lower P/E often reflects how the market weighs growth potential and business risk, so a “normal” or “fair” P/E tends to be higher for companies with stronger earnings prospects and lower perceived risk, and lower for those with weaker outlooks or higher uncertainty.

Haemonetics currently trades on a P/E of about 15.7x. That sits below the Medical Equipment industry average P/E of around 23.6x and also below the peer group average of about 25.6x. On the surface, that points to a lower earnings multiple than many similar companies in the same space.

Simply Wall St’s Fair Ratio for Haemonetics is 25.4x. This is a proprietary estimate of what the P/E could be given factors such as the company’s earnings growth profile, its industry, profit margins, market cap and risk characteristics. Because it blends these company specific inputs, the Fair Ratio can give a more tailored reference point than a simple comparison with industry or peer averages. Set against the current P/E of 15.7x, the Fair Ratio suggests the shares are trading below that tailored benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Haemonetics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives bring your view of Haemonetics together in one place by linking the story you believe in, your forecast for revenue, earnings and margins, and the Fair Value you think is reasonable. You can then compare that Fair Value with the current price to help you decide whether the shares look attractive or expensive.

On Simply Wall St’s Community page, you can select or build a Narrative that fits your outlook. It will automatically refresh as new information such as news, guidance or earnings is added, so your view does not go stale.

For Haemonetics, one investor might lean toward a cautious Narrative that aligns with a Fair Value around US$64, while another might prefer a more optimistic Narrative closer to US$108. Seeing those side by side helps you judge which story and which Fair Value better match your expectations before making any buy or sell decisions.

Do you think there's more to the story for Haemonetics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.